These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27304187)

  • 1. Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.
    Spagnuolo RD; Brich S; Bozzi F; Conca E; Castelli C; Tazzari M; Maestro R; Brenca M; Gualeni AV; Gloghini A; Stacchiotti S; Pierotti MA; Pilotti S; Negri T
    Oncotarget; 2016 Jul; 7(29):45015-45026. PubMed ID: 27304187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy.
    Tazzari M; Negri T; Rini F; Vergani B; Huber V; Villa A; Dagrada P; Colombo C; Fiore M; Gronchi A; Stacchiotti S; Casali PG; Pilotti S; Rivoltini L; Castelli C
    Br J Cancer; 2014 Sep; 111(7):1350-62. PubMed ID: 25101565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
    Stacchiotti S; Negri T; Palassini E; Conca E; Gronchi A; Morosi C; Messina A; Pastorino U; Pierotti MA; Casali PG; Pilotti S
    Mol Cancer Ther; 2010 May; 9(5):1286-97. PubMed ID: 20457621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib malate in solitary fibrous tumor (SFT).
    Stacchiotti S; Negri T; Libertini M; Palassini E; Marrari A; De Troia B; Gronchi A; Dei Tos AP; Morosi C; Messina A; Pilotti S; Casali PG
    Ann Oncol; 2012 Dec; 23(12):3171-3179. PubMed ID: 22711763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
    Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
    Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux.
    Giuliano S; Cormerais Y; Dufies M; Grépin R; Colosetti P; Belaid A; Parola J; Martin A; Lacas-Gervais S; Mazure NM; Benhida R; Auberger P; Mograbi B; Pagès G
    Autophagy; 2015; 11(10):1891-904. PubMed ID: 26312386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
    Stacchiotti S; Tortoreto M; Bozzi F; Tamborini E; Morosi C; Messina A; Libertini M; Palassini E; Cominetti D; Negri T; Gronchi A; Pilotti S; Zaffaroni N; Casali PG
    Clin Cancer Res; 2013 Sep; 19(18):5192-201. PubMed ID: 23888069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
    Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
    Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
    Santoni M; Amantini C; Morelli MB; Liberati S; Farfariello V; Nabissi M; Bonfili L; Eleuteri AM; Mozzicafreddo M; Burattini L; Berardi R; Cascinu S; Santoni G
    Br J Cancer; 2013 Aug; 109(4):1040-50. PubMed ID: 23887605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries.
    Abdel-Aziz AK; Mantawy EM; Said RS; Helwa R
    Exp Neurol; 2016 Sep; 283(Pt A):129-41. PubMed ID: 27288242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
    BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib in kidney cancer: 10 years of experience and development.
    Nassif E; Thibault C; Vano Y; Fournier L; Mauge L; Verkarre V; Timsit MO; Mejean A; Tartour E; Oudard S
    Expert Rev Anticancer Ther; 2017 Feb; 17(2):129-142. PubMed ID: 27967249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.
    Abdel-Aziz AK; Shouman S; El-Demerdash E; Elgendy M; Abdel-Naim AB
    Chem Biol Interact; 2014 Jun; 217():28-40. PubMed ID: 24751611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway.
    Kimura T; Uesugi M; Takase K; Miyamoto N; Sawada K
    Toxicol Appl Pharmacol; 2017 Aug; 329():282-292. PubMed ID: 28624441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
    Sablin MP; Dreyer C; Colichi C; Bouattour M; Delbaldo C; Faivre S; Raymond E
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1005-15. PubMed ID: 20636223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
    Voce P; D'Agostino M; Moretti S; Sponziello M; Rhoden K; Calcinaro F; Tamburrano G; Tallini G; Puxeddu E; Filetti S; Russo D; Durante C
    Oncol Rep; 2011 Nov; 26(5):1075-80. PubMed ID: 21850379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer.
    Suchy SL; Hancher LM; Wang D; Ervin PR; Brower SL
    Cancer Biol Ther; 2011 Jun; 11(12):1059-64. PubMed ID: 21525781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
    Wang S; Mou Z; Ma Y; Li J; Li J; Ji X; Wu K; Li L; Lu W; Zhou T
    Biochem Pharmacol; 2015 May; 95(2):98-109. PubMed ID: 25824241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Knockdown of ATG5 enhances the sensitivity of human renal carcinoma cells to sunitinib].
    Li P; Han Q; Tang M; Zhang K
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Mar; 33(3):367-371. PubMed ID: 28274318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells.
    Zhao Y; Xue T; Yang X; Zhu H; Ding X; Lou L; Lu W; Yang B; He Q
    Toxicol Appl Pharmacol; 2010 Oct; 248(1):20-7. PubMed ID: 20637791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.